Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Phase 2 Recruiting
92 enrolled
BELLWAVE-011
Phase 3 Recruiting
1,200 enrolled
TAILOR
Phase 2 Recruiting
320 enrolled
QOLIBRI
Recruiting
180 enrolled
BRUIN-CLL-314
Phase 3 Recruiting
662 enrolled
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Phase 1/2 Recruiting
320 enrolled
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2 Recruiting
496 enrolled
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Phase 1 Recruiting
55 enrolled
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Phase 1/2 Recruiting
37 enrolled
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Phase 1 Recruiting
26 enrolled
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Phase 2 Recruiting
30 enrolled
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
Phase 1/2 Recruiting
27 enrolled
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Phase 1 Recruiting
37 enrolled
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Phase 2 Recruiting
40 enrolled
Mosunetuzumab for CLL MRD Clearance
Phase 1/2 Recruiting
40 enrolled
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
Phase 2 Recruiting
79 enrolled
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
Phase 2 Recruiting
90 enrolled
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Phase 2 Recruiting
40 enrolled
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Phase 1/2 Recruiting
123 enrolled
CARMAN
Phase 2 Recruiting
150 enrolled
RAINBOW
Phase 2/3 Recruiting
148 enrolled
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Phase 2 Recruiting
45 enrolled
VALUABLE
Phase 2 Recruiting
55 enrolled
FIGHT
Phase 2 Recruiting
53 enrolled
IbruOnOff
Phase 1/2 Recruiting
50 enrolled
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
Phase 3 Recruiting
870 enrolled